Skip to main content
Livermore
Livermore
ZHEN

Avenue Therapeutics, Inc.

ATXI
Exchange
OTC
Industry
Pharmaceutical Preparations
SEC CIK
0001644963

No open-market purchases or sales by Avenue Therapeutics, Inc. insiders were filed in the last 90 days; no institution reported holding it in 13F filings for Q2 2026; no superinvestor holds it.

Holders of 5% or more of ATXI

Holders whose latest Schedule 13D or 13G filing reports 5% or more of Avenue Therapeutics, Inc., largest stake first. The change is against the holder's previous filing.

Holders of 5% or more of ATXI
HolderLatest formStakeChangeFirst filedLatest filingFiling
Fortress Biotech, Inc.13D/A13.40%440.0K shares+3.10 ppfrom 10.30%Jan 3, 20253 filingsJan 6, 2026SEC

Stakes are as of each holder's latest filing. Holders whose last filing was in the old format (before December 18, 2024) have no stake on record and are not listed, and after an acquisition or delisting holders usually stop filing.

13D and 13G filings

6 Schedule 13D and 13G filings on Avenue Therapeutics, Inc., newest first, including old-format filings without a stake.

Schedule 13D and 13G filings on ATXI
Filed (ET)FilerFormStakeChangeEvent dateFiling
Feb 17, 20265:09 PM ETIkarian Capital, LLCand 1 other13G/A4.10%130.8K shares−2.70 ppfrom 6.80%Below 5%Dec 31, 2025SEC
Jan 6, 20264:11 PM ETFortress Biotech, Inc.13D/A13.40%440.0K shares+3.10 ppfrom 10.30%Jan 2, 2026SEC
Apr 2, 20255:00 PM ETFortress Biotech, Inc.13D/A10.30%328.7K shares−3.50 ppfrom 13.80%Mar 31, 2025SEC
Feb 14, 20255:01 PM ETArmistice Capital, LLCand 1 other13G/A4.99%100.4K shares–Below 5%Dec 31, 2024SEC
Feb 14, 20251:25 PM ETIkarian Capital, LLCand 1 other13G6.80%140.0K sharesNewDec 31, 2024SEC
Jan 3, 20255:50 PM ETFortress Biotech, Inc.13D/A13.80%295.0K shares–Dec 31, 2024SEC

Form 144: proposed insider sales

Notices from officers, directors and other affiliates planning to sell Avenue Therapeutics, Inc. shares.

No Form 144 notices for Avenue Therapeutics, Inc. are on file.